Catalog No. |
TD-HY257126 |
Species reactivity |
Human |
Applications |
Research Grade Biosimilar |
Host species |
Humanized |
Isotype |
IgG1-kappa |
Expression system |
Mammalian Cells |
Species |
Human |
Clonality |
Monoclonal |
Target |
B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20 |
Endotoxin level |
Please contact with the lab for this information. |
Purity |
>95% as determined by SDS-PAGE. |
Purification |
Protein A/G purified from cell culture supernatant. |
Accession |
P11836 |
Form |
Liquid |
Storage buffer |
0.01M PBS, pH 7.4. |
Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
Alternate Names |
AME-133v, LY2469298, CAS: 1169956-08-4 |
Background |
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC). |
Note |
For research use only. Not suitable for clinical or therapeutic use. |